These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

901 related items for PubMed ID: 24918792

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J, Sands M, Burciu C, Reaven P.
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B.
    J Cardiovasc Nurs; 2016 May; 31(3):274-83. PubMed ID: 25829138
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, Xie J, Yang Y, Yu X.
    Cardiovasc Diabetol; 2017 Mar 01; 16(1):31. PubMed ID: 28249585
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular Effects of Incretin-Based Therapies.
    White WB, Baker WL.
    Annu Rev Med; 2016 May 11; 67():245-60. PubMed ID: 26768240
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E, Monami M.
    Adv Ther; 2017 Jan 11; 34(1):1-40. PubMed ID: 27844335
    [Abstract] [Full Text] [Related]

  • 14. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
    Jain R.
    Adv Ther; 2015 Nov 11; 32(11):1065-84. PubMed ID: 26578430
    [Abstract] [Full Text] [Related]

  • 15. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB.
    Postgrad Med; 2012 Jul 11; 124(4):54-61. PubMed ID: 22913894
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M.
    Diabetes Obes Metab; 2013 Jul 11; 15(7):593-606. PubMed ID: 23216746
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS.
    Cleve Clin J Med; 2009 Dec 11; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.